Zacks Investment Research upgraded shares of Eisai (OTCMKTS:ESALY) from a strong sell rating to a hold rating in a report published on Monday morning.

According to Zacks, “Eisai Co LTD is involved in the Biotechnology and Drug Industry. Their principle activities are the manufacture and sale of pharmaceutical products. Operations are carried out through the following divisions: Pharmaceuticals: veterinary drugs other food additives, livestock feed and pharmaceutical production systems and equipment. The Group has overseas consolidated subsidiaries in the United States, Canada, the United Kingdom, France, Germany, East Southeast Asia and South and Central America. “

Eisai (OTCMKTS ESALY) opened at $59.95 on Monday. Eisai has a one year low of $50.31 and a one year high of $63.06. The company has a quick ratio of 1.81, a current ratio of 2.18 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $17,304.69, a price-to-earnings ratio of 62.45 and a beta of -0.25.

TRADEMARK VIOLATION WARNING: This story was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at

Eisai Company Profile

Eisai Co, Ltd. is engaged in the research and development, manufacture, sale and import and export of pharmaceuticals. The Company’s businesses include pharmaceutical business and other business. The Company’s segments include Japan (Prescription Medicines, Generics and Diagnostics), Americas (North America, Central and South America), China, Asia (South Korea, Taiwan, Hong Kong, India and ASEAN), EMEA (Europe, the Middle East, Africa and Oceania) and Consumer Healthcare Business-Japan.

Get a free copy of the Zacks research report on Eisai (ESALY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai and related companies with Analyst Ratings Network's FREE daily email newsletter.